Nobels Amandine, van Marcke Cédric, Jordan Bénédicte F, Van Hul Matthias, Cani Patrice D
UCLouvain, Université catholique de Louvain, Louvain Drug Research Institute (LDRI), Metabolism and Nutrition Research Group (MNUT), Brussels, Belgium.
UCLouvain, Université catholique de Louvain, Institut de Recherche Expérimentale et Clinique (IREC), Pole of Medical Imaging, Radiotherapy and Oncology (MIRO), Brussels, Belgium.
Nat Metab. 2025 May 6. doi: 10.1038/s42255-025-01287-w.
The gut microbiome has a crucial role in cancer development and therapy through its interactions with the immune system and tumour microenvironment. Although evidence links gut microbiota composition to cancer progression, its precise role in modulating treatment responses remains unclear. In this Review, we summarize current knowledge on the gut microbiome's involvement in cancer, covering its role in tumour initiation and progression, interactions with chemotherapy, radiotherapy and targeted therapies, and its influence on cancer immunotherapy. We discuss the impact of microbial metabolites on immune responses, the relationship between specific bacterial species and treatment outcomes, and potential microbiota-based therapeutic strategies, including dietary interventions, probiotics and faecal microbiota transplantation. Understanding these complex microbiota-immune interactions is critical for optimizing cancer therapies. Future research should focus on defining microbial signatures associated with treatment success and developing targeted microbiome modulation strategies to enhance patient outcomes.
肠道微生物群通过与免疫系统和肿瘤微环境的相互作用,在癌症的发生发展及治疗中发挥着关键作用。尽管有证据表明肠道微生物群的组成与癌症进展相关,但其在调节治疗反应中的具体作用仍不清楚。在本综述中,我们总结了目前关于肠道微生物群参与癌症的知识,涵盖其在肿瘤起始和进展中的作用、与化疗、放疗和靶向治疗的相互作用,以及对癌症免疫治疗的影响。我们讨论了微生物代谢产物对免疫反应的影响、特定细菌种类与治疗结果之间的关系,以及基于微生物群的潜在治疗策略,包括饮食干预、益生菌和粪便微生物群移植。了解这些复杂的微生物群-免疫相互作用对于优化癌症治疗至关重要。未来的研究应集中于确定与治疗成功相关的微生物特征,并开发有针对性的微生物群调节策略,以改善患者的治疗效果。